GlaxoSmithKline plc (NYSE:GSK) – Stock analysts at Jefferies Financial Group issued their Q1 2019 earnings estimates for GlaxoSmithKline in a research report issued on Tuesday, February 12th. Jefferies Financial Group analyst P. Welford forecasts that the pharmaceutical company will post earnings per share of $0.60 for the quarter. Jefferies Financial Group has a “Buy” rating and a $45.00 price objective on the stock. Jefferies Financial Group also issued estimates for GlaxoSmithKline’s Q2 2019 earnings at $0.65 EPS, Q3 2019 earnings at $0.91 EPS, Q4 2019 earnings at $0.75 EPS, FY2019 earnings at $2.89 EPS, FY2021 earnings at $3.56 EPS, FY2022 earnings at $3.85 EPS and FY2023 earnings at $4.13 EPS.
Other analysts also recently issued research reports about the company. Morgan Stanley initiated coverage on GlaxoSmithKline in a report on Friday, December 14th. They set an “underweight” rating on the stock. BNP Paribas downgraded GlaxoSmithKline from an “outperform” rating to a “neutral” rating in a report on Monday, January 14th. Exane BNP Paribas downgraded GlaxoSmithKline from an “outperform” rating to a “neutral” rating in a report on Monday, January 14th. Wolfe Research started coverage on GlaxoSmithKline in a report on Tuesday, October 23rd. They issued a “market perform” rating on the stock. Finally, ValuEngine upgraded GlaxoSmithKline from a “sell” rating to a “hold” rating in a report on Friday, October 19th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $41.71.
Shares of GlaxoSmithKline stock opened at $40.37 on Wednesday. The company has a current ratio of 0.75, a quick ratio of 0.51 and a debt-to-equity ratio of 5.52. GlaxoSmithKline has a 52 week low of $35.78 and a 52 week high of $42.36. The stock has a market capitalization of $100.54 billion, a price-to-earnings ratio of 12.78, a price-to-earnings-growth ratio of 2.15 and a beta of 0.79.
GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings results on Wednesday, February 6th. The pharmaceutical company reported $0.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.70 by $0.09. GlaxoSmithKline had a net margin of 11.45% and a return on equity of 160.39%. The company had revenue of $10.55 billion during the quarter, compared to the consensus estimate of $9.85 billion.
The business also recently announced a quarterly dividend, which will be paid on Thursday, April 11th. Shareholders of record on Friday, February 22nd will be given a dividend of $0.597 per share. The ex-dividend date of this dividend is Thursday, February 21st. This represents a $2.39 dividend on an annualized basis and a yield of 5.92%. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.49. GlaxoSmithKline’s dividend payout ratio is presently 60.76%.
A number of institutional investors have recently made changes to their positions in the business. Courier Capital LLC boosted its position in shares of GlaxoSmithKline by 3.0% in the fourth quarter. Courier Capital LLC now owns 9,025 shares of the pharmaceutical company’s stock valued at $345,000 after acquiring an additional 260 shares during the period. Buckhead Capital Management LLC boosted its position in shares of GlaxoSmithKline by 1.2% in the fourth quarter. Buckhead Capital Management LLC now owns 24,940 shares of the pharmaceutical company’s stock valued at $953,000 after acquiring an additional 300 shares during the period. River Wealth Advisors LLC boosted its position in shares of GlaxoSmithKline by 17.8% in the fourth quarter. River Wealth Advisors LLC now owns 1,990 shares of the pharmaceutical company’s stock valued at $76,000 after acquiring an additional 301 shares during the period. Comerica Securities Inc. boosted its position in shares of GlaxoSmithKline by 2.6% in the fourth quarter. Comerica Securities Inc. now owns 12,984 shares of the pharmaceutical company’s stock valued at $502,000 after acquiring an additional 326 shares during the period. Finally, Cozad Asset Management Inc. boosted its position in shares of GlaxoSmithKline by 2.3% in the fourth quarter. Cozad Asset Management Inc. now owns 15,793 shares of the pharmaceutical company’s stock valued at $603,000 after acquiring an additional 357 shares during the period. 10.89% of the stock is owned by hedge funds and other institutional investors.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Story: Insider Trading
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.